MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Press releases

Stay current with the latest press releases from within the industry.

Astrazeneca's Seroquel will overtake GlaxoSmithKline's Lamictal by 2010 as the gold standard for the treatment of Bipolar Depression

Release issued 21st February 2007

February 20, 2007, Waltham, Mass.   - Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that AstraZeneca's Seroquel will overtake GlaxoSmithKline's Lamictal as the gold standard in the treatment of bipolar depression by 2010. According to the new report entitled Bipolar Depression: Turning Physician Insight into Projected Market Share , Seroquel's advantages over Lamictal include the more profound effect on depressive symptoms seen in short-term trials. The drug's efficacy on this measure differentiates it from other therapies, according to thought-leading psychiatrists, and the importance assigned to this measure by prescribing psychiatrists drives Seroquel's product score above Lamictal's.*

The report also sizes other opportunities in this market, based on prescribing psychiatrists' satisfaction with currently available agents.

"During the next 10-15 years, we expect that only two other therapies will receive labeling for the treatment of bipolar depression: BMS/Otsuka's Abilify and Wyeth/Solvay/Lundbeck's bifeprunox," said Kate Hohenberg, principal director at Decision Resources. "Neither drug has yet demonstrated a notable improvement in efficacy over currently available atypical antipsychotics in the treatment of schizophrenia or bipolar disorder, but we still expect them to have a market. Abilify exhibits a much lower risk of sedation and somnolence than the atypical antipsychotics according to pooled clinical trial data in its product insert, and our target product profile research reveals an opportunity for this agent as well. We expect bifeprunox will share this characteristic."

About Bipolar Depression: Turning Physician Insight into Projected Market Share

Bipolar Depression: Turning Physician Insight into Projected Market Share covers the current and future state of the bipolar depression drug market. The report includes the following:

  • More than 3,000 physician responses that define the drug attributes that drive prescription, now and in the future.
    - Clinical endpoint tradeoffs that are most influential to physicians.
    - Areas of unmet need with highest potential.
    - Benchmark trial results for specific drug opportunities.
    - Patient share potential for emerging therapies and target product profiles.
  • Decision Resources' proprietary analysis of commercial factors that accelerate or constrain a drug's market potential.
    - Promotion: DTC spend, detailing intensity.
    - Reimbursement: formulary tier, prior approval restriction, quantity limits.
    - Labeling: black box warnings, approved patient segments, contraindications.
    - Competition: order of entry, pricing, generic entry, pipeline sales forecast.
    - Medical practice: decision trees, treating physician type, line of therapy.
  • Comparisons of the key clinical attributes of current and emerging therapies in the areas of efficacy, safety, and delivery.
  • Analysis and supporting data that identify the clinical "Gold Standard" now, and over the next ten years.
  • Key insights as to which clinical end points have the greatest influence on physician decision-making.

The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy or an interview with an analyst.

About Decision Resources
Decision Resources ( www.decisionresources.com ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.


###

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


 

Company details

If you want to find out more about the company visit Decision Resources Inc. profile.

Latest Decision Resources Inc. press releases

More Press Releases

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us